Published in final edited form as:

Mol Cancer Ther. 2013 October ; 12(10): . doi:10.1158/1535-7163.MCT-12-0962.

Catalase abrogates β -lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers

Erik A. Bey^{1,*}, Kathryn E. Reinicke², Melissa C. Srougi³, Marie Varnes², Vernon Anderson², John J. Pink⁴, Long Shan Li⁵, Malina Patel⁵, Lifan Cao⁵, Zachary Moore⁵, Amy Rommel⁵, Michael Boatman¹, Cheryl Lewis⁶, David M. Euhus⁶, William G. Bornmann⁷, Donald J. Buchsbaum⁸, Douglas R. Spitz⁹, Jinming Gao⁵, and David A. Boothman^{5,*}

¹Department of Basic Pharmaceutical Sciences, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia 26506

²Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106

³Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106

⁴Department of Oncology, Case Western Reserve University, Cleveland, Ohio 44106

⁵Department of Pharmacology, Laboratory of Molecular Cell Stress Responses, Program in Cell Stress and Cancer Nanomedicine, Simmons Cancer Center, UT Southwestern Medical Center at Dallas, TX 75390-8807

⁶Department of Surgery, UT Southwestern Medical Center at Dallas, TX 75390

⁷Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX 77030

⁸Department of Radiation Oncology, University of Alabama-Birmingham, Birmingham, Alabama, 35233

⁹Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242

Abstract

Improving patient outcome by personalized therapy involves a thorough understanding of an agent's mechanism of action. β -Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme, NAD(P)H:quinone oxidoreductase (NQO1). NQO1 is dramatically elevated in solid cancers, including primary and metastatic (e.g., triple-negative (ER-, PR-, Her2/Neu-)) breast cancers. To define cellular factors that influence the efficacy of β -lapachone using knowledge of its mechanism of action, we confirmed that NQO1 was required for lethality and mediated a futile redox cycle where ~ 120 moles of superoxide were formed per mole of β -lapachone in 5 min. β -Lapachone induced reactive oxygen species (ROS), stimulated DNA single strand break-dependent PARP1 hyperactivation, caused dramatic loss of essential nucleotides (NAD⁺/ATP) and elicited programmed necrosis in breast cancer cells. While PARP1 hyperactivation and NQO1 expression were major determinants of β -lapachone-induced lethality, alterations in catalase expression, including treatment with

***Corresponding Authors:** *Erik A. Bey, West Virginia University, 1 Medical Center Drive, Box 9300, Room 1835, Morgantown West Virginia, 26506 (ebey@hsc.wvu.edu); or *David A. Boothman, University of Texas South Western Medical Center at Dallas, 6001 Forest Park Drive, ND2.210K, Mail stop 8807, Dallas Texas, 75390-8807 (David.Boothman@UTSouthwestern.edu). This paper is dedicated to Dr. Marie Varnes, Emeritus Professor of Radiation Oncology, CWRU who began these studies.

Conflicts of interest

Drs. Boothman and Gao are consultants for Bistemics & Stempar Sciences, Inc. There are no additional conflicts of interest.

exogenous enzyme, caused marked cytoprotection. Thus, catalase is an important resistance factor, and highlights H_2O_2 as an obligate ROS for cell death from this agent. Exogenous superoxide dismutase (SOD) enhanced catalase-induced cytoprotection. α -Lapachone-induced cell death included AIF translocation from mitochondria to nuclei, TUNEL+ staining, atypical PARP1 cleavage, and GAPDH S-nitrosylation, which were abrogated by catalase. We predict that the ratio of NQO1:catalase activities in breast cancer versus associated normal tissue are likely to be the major determinants affecting the therapeutic window of α -lapachone and other NQO1 bioactivatable drugs.

Keywords

Breast cancer; Catalase; Super Oxide Dismutase, α -Lapachone; NADPH quinone oxidoreductase-1; Poly (ADP-ribose) polymerase-1; Programmed necrosis

Introduction

Approximately one in eight women will be diagnosed with breast cancer in their lifetimes in the U.S. (1). Most current therapeutic strategies designed to treat breast cancer, as with other cancers, attack proliferative differences between tumor and associated normal breast tissue. These approaches frequently result in minimal efficacy, undesirable normal tissue toxicity, and often result in selection of drug resistant, aggressive cancer cells undergoing epithelial-to-mesenchymal transition, with increased metastatic potential (2–5). Since caspase pathways are commonly abrogated or altered in breast or other cancers (6), strategies for treating cycling, as well as dormant cancer cells, that exploit caspase-independent cell death pathways (e.g., programmed necrosis) are desperately needed. Few drugs mechanistically act to induce poly(ADP-ribose) polymerase-1 (PARP1)-mediated programmed necrosis in a tumor-specific manner and at clinically relevant doses (7). Most agents known to stimulate PARP1-mediated programmed necrosis (e.g., N-methyl, N'-nitro, N-nitrosoguanidine (>5 mmol/L MNNG) or hydrogen peroxide (>200 μ mol/L H_2O_2) (8, 9) do so at supra-lethal, non-achievable doses clinically. In contrast, α -lapachone (α -lap, see Figure 1 for structure) stimulates PARP1 hyperactivation and causes dramatic intracellular nucleotide loss, particularly in NAD⁺ and ATP pools (10), at clinically achievable doses. PARP1 uses NAD⁺ as a substrate to perform poly(ADP-ribosylation) (PAR) post-translational modification of proteins, including itself, where poly(ADP-ribosylated)-PARP1 (PAR-PARP1) is functionally inactive.

α -Lap is efficacious against solid tumors that have endogenously over-expressed NAD(P)H:quinone oxidoreductase I (NQO1), including >80% non-small cell lung and pancreatic, as well as >60% prostate and >70% breast cancers, where 5- to >100-fold increases in NQO1 activities above associated normal tissue were reported (11–13). α -Lap undergoes an NQO1-dependent futile redox cycle (Figure 1A), where >60 moles of NAD(P)H are consumed per mole α -lap in 1–2 min (12, 14–18). This futile cycle results from the instability of its hydroquinone and semiquinone forms, presumably consuming oxygen and theoretically creating dramatically elevated levels of superoxide ($O_2^{\cdot-}$). Combined DNA damage and Ca^{2+} release from endoplasmic reticulum (Ca^{2+}_{ER}) stores culminates in PARP1 hyperactivation, NAD⁺/ATP loss, DNA repair inhibition, and programmed necrosis by unknown protein effectors (12, 16–19). The majority of reported cellular effects in α -lap-treated cancer cells are actually the result of dramatic NAD⁺/ATP losses (reviewed in (20)). Understanding the role(s) of reactive oxygen species (ROS) and ROS scavenging enzymes in deterring the efficacy of α -lap or Deoxynyboquinone (DNQ), the only other NQO1 bioactivatable drug (7) against NQO1 over-expressed solid cancers remains unexplored.

Here, we report a potential mechanism of resistance to γ -lap-induced cell death by catalase, potentiated by superoxide dismutase (SOD). PARP1 hyperactivation was the major determinant of downstream programmed necrosis initiation when sublethal to lethal doses of γ -lap were compared. Exposure of NQO1+ cells to sublethal γ -lap doses (1 μ mol/L) caused enhanced O₂ consumption, ROS formation and single strand breaks (SSBs), however, DNA lesions were below an apparent 'threshold damage level' required for PARP1 hyperactivation. In contrast, lethal γ -lap doses (2 μ mol/L) that killed 50% NQO1+ MDA-MB-231 triple-negative breast cancer cells (TNBC, Supplemental Table 1) stimulated PARP1 hyperactivation causing dramatic NAD⁺/ATP losses. As a result, apoptosis inducing factor (AIF) activation and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) modification were noted that corresponded to programmed necrosis. Catalase spared γ -lap-treated cells from H₂O₂ (but not O₂^{•-}) formation, PARP1 hyperactivation, AIF activation, atypical PARP1 and p53 proteolysis, blocked TUNEL+ staining, and enhanced clonogenic survival. The cytoprotective effects of catalase were enhanced by SOD co-addition, consistent with an obligate role of H₂O₂ in γ -lap-induced lethality. While inhibiting AIF expression slightly protected cells from γ -lap-induced lethality, altering downstream protein effectors were much less effective than altering upstream processes, such as scavenging ROS or chelating Ca²⁺_{ER} at preventing lethality. The ratio of NQO1/catalase expression in tumor versus normal tissue may be a major determinant in the efficacy of antitumor regimen involving NQO1 bioactivatable drugs, such as γ -lap.

Materials and Methods

Chemicals, reagents and antibodies

γ -Lap (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione, Figure 1) was synthesized by us, confirmed by NMR, dissolved in DMSO at 50 μ mol/L, and concentrations verified by spectrophotometry (15). Menadione and Doxorubicin (DOX) were obtained from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO or PBS (DOX) respectively. Dicoumarol (DIC, Sigma-Aldrich) was used as described (15). 5-(and-6)Chloromethyl-2,7-dichlorodihydrofluorescein diacetate (DCFDA, 5 μ mol/L) and Dihydroethidium (DHE, 5 μ mol/L) used to assess ROS formation were purchased from (Invitrogen) and used as described previously (18, 19). N-acetyl-L-cysteine (NAC, Sigma-Aldrich) was used at 5 mmol/L for 24 h pre-treatments and 2 h co-treatments as described (21). Xanthine, nitroblue tetrazolium (NBT), diethylenetriaminepentaacetic acid (DETAPAC), catalase, SOD, bovine serum albumin (BSA), bathocuproine disulfonic acid (BCS) disodium salt hydrate, and xanthine oxidase (Sigma-Aldrich) were used as described (22). Staurosporine (STS) and the pan-caspase inhibitor, zVAD-FMK (Z-VAD) were obtained and used as described (12, 14–18) (See structures, Supplemental Figure S1). In transient AIF knock-down experiments AIF (siAIF), NQO1 (si-NQ) and scrambled (SCR) siRNAs were purchased from (Dharmacon).

Cell lines, Cell culture, treatments and survival

MDA-MB-231 TNBC cells lacking or expressing NQO1 and MCF-7:WS8 (MCF-7) cells were grown as described (15, 17). Additional breast cancer cell lines were purchased from ATTC, MAP-tested and were free of mycoplasma. Breast cancer cell lines were grown in RPMI 1640 media at 37 °C in a humidified 10% CO₂-95% air atmosphere. Human mammary epithelial cells (HMEC 1585) were isolated from normal human mammary epithelial tissue of a patient without breast cancer and subjected to DNA finger printing. HMEC were grown in MEGM/DMEM-F12 complete media (Lonza and Mediatech) at 37 °C in a humidified 10% CO₂-95% air atmosphere. Relative survival assays were performed as described (15). Experiments were repeated at least three times, and data expressed as relative survival (treated/control $\times$ 100%) means $\pm$ SE. Results using this assay directly

correlated with clonogenic assays (15). A multi-target model was used to describe the shape of relative survival curves, where the final slope (D_0) and quasi-threshold (D_q) doses were used to represent the size or width of the shoulder. Three parameters, n (extrapolation number), D_0 , and D_q were related as: $\log_e n = D_q/D_0$. In experiments with catalase, bovine catalase (Sigma-Aldrich) was dissolved in 5 mmol/L Hepes buffer (pH 7.4) or phosphate buffered saline. Dissolved catalase was filter sterilized and added to drug media prior to exposure to drug treatment.

O₂ consumption rates (OCRs)

were measured using an Ocean Optics, Inc. (Dunedin, FL) Foxy-18G-AF oxygen sensor and S9 supernatants (15). S9 extracts were added to a closed system in Tris-HCl buffer containing 10% BSA, pH 7.5, 0.5 mmol/L NADH, $-\text{lap} \pm 40 \mu\text{mol/L}$ DIC (23). The OOI Sensors program (Ocean Optics, Inc.) was used to quantify fluorescence at 599.62 nm every 512 seconds, averaging every four readings. Data (means, $\pm$ SE) were graphed as X-fold OCR from three independent experiments, each performed in triplicate. In addition to Ocean Optics experiments, OCRs were confirmed in 231-NQ+ and 231-NQ-cells using a Seahorse XF24 extracellular flux analyzer (Seahorse Biosciences) as described previously (7). Briefly 25,000 231 NQ+ or 231 NQ-cells were seeded in Seahorse 24-well microplates. Prior to analysis cells were left untreated (control) or treated with $4 \mu\text{mol/L}$ $-\text{lap}$ with or without DIC. OCR were measured as previously described (7). Data represent means, % treated/control (% T/C), $\pm$ SE from quadruplicate assessments.

ROS, NAD⁺ and ATP measurements

Cellular oxidative stress was assessed by reduced/total glutathione, %GSSG content (17), and normalized to protein (24). Experiments were performed three times and data expressed as means, $\pm$ SE. ROS formation was assessed microscopically in 231 NQ+ and NQ-cells stained with DCFDA or DHE. Quantitative data obtained from digital images of at least 100 cells were analyzed using NIH ImageJ software. Changes in intracellular NAD⁺ levels were measured (17) and data expressed as %NAD⁺ (% treated/control) means, $\pm$ SE for experiments performed three times in triplicate.

Comet assays

DNA damage was assessed by alkaline comet assays, tail migration distance measured and analyzed using NIH ImageJ software (17). Comet tail lengths were measured in microns and mean lengths, $\pm$ SE reported from three independent experiments performed in triplicate.

Apoptosis

TUNEL assays were performed (16) and data expressed as means, $\pm$ SE from three separate experiments.

Western blotting and antibodies

Western blot analyses were performed as described (15). $-\text{PAR}$ and $-\text{H}_2\text{AX}$ were used as described (17). $-\text{PARP1}$ (SC-8007, 1:2,000), $-\text{AIF}$ (SC-5586, 1:2000), $-\alpha$ -tubulin (1:10,000) and $-\text{GAPDH}$ (SC-25778 and 32233, 1:50,000) were from Santa Cruz. Additional $-\text{GAPDH}$ antibodies (CB-1001, 1:50,000) and (ab-9485, 1:50,000) were purchased from Calbiochem (Sandiego, CA) and from Abcam (Cambridge, MA), respectively. Relative PAR levels were calculated by densitometric analyses using NIH ImageJ using PARP1 loading controls. Measurements were normalized to $t = 0$ levels. Western blots shown were representative of separate experiments performed at least three times.

Statistics

All experiments were repeated at least twice in triplicate. Student's *t* tests were performed to compare conditions and data were reported as means, $\pm$ SE.

Results

β -Lap-induced, NQO1-dependent O₂ consumption

NQO1-driven futile redox cycling of β -lap (Figure 1A) (15) predicted a robust OCR, with concomitant rapid and dramatic O₂^{•-} and H₂O₂ formation. Using MDA-MB-231 TNBC cells expressing (231-NQ+) or lacking (231-NQ-) NQO1, we directly measured OCR in a closed system with an Ocean Optics O₂ sensor (Figure 1B, left). Appropriate controls using KCN and oligomycin, inhibitors of the electron transport chain, were performed (Supplemental Figure S2). NADH, β -lap and NQO1 enzymatic activity were necessary components for robust futile redox cycling and elevated OCR, since DIC prevented dose-dependent, β -lap-induced OCR increases (~40-fold in 5 min after 15 μ mol/L) in 231-NQ+ cells. Significant increases in OCR were noted in NQO1+ cells exposed to 2 μ mol/L versus 1 μ mol/L β -lap (Figure 1B, left). In contrast, 231-NQ-cells showed no OCR increases after β -lap, up to 15 μ mol/L (Figure 1B, left). OCRs in 231-NQ+cells exposed to 4 μ mol/L β -lap were then confirmed using the Seahorse monitoring systems as previously described (7). β -Lap (4 μ mol/L) exposure caused an immediate burst in OCRs that were inhibited by DIC, and dissipated over the next 100 min (Figure 1B, right). NQO1-dependent OCRs were accompanied by dramatic increases in O₂^{•-} (Figure 1C) and H₂O₂ (Figure 1D). The absence of significant ROS in NQO1-cells strongly suggested that within the 2–4 h exposure of cells to β -lap (4 μ mol/L), the drug was a relatively poor substrate for one-electron oxidoreductions, mediated by b5R and p450R oxidoreductases (17) (Figure 1A). Cells exposed to doxorubicin (DOX, 5 μ mol/L, 30 min) or H₂O₂ (200 μ mol/L, 30 min) resulted in statistically equivalent O₂^{•-} or H₂O₂ levels, respectively, in 231-NQ- or 231-NQ+ cells (Figures 1C, D), suggesting that scavenging enzymes/factors present were equivalent in these NQO1 isogenic cells.

Lethal β -lap doses cause threshold levels of DNA damage required for PARP1 hyperactivation

Survival responses of NQO1+ human cancer cells to increasing β -lap concentrations are rather sharp, where 1–1.8 μ mol/L treatments for 2–4 h were not lethal, but incremental increases to 2–3 μ mol/L caused >90% cell death responses, indicated by strong TUNEL+ staining (15, 17, 21). We hypothesized that these sharp dose-responses were due not only to futile redox cycling of β -lap in NQO1+ cells expressing ~100 units of NQO1 (19), but that differences between sublethal and lethal doses of the drug were due to achieving a critical threshold level of DNA lesions (specifically base damage and SSBs) that ultimately hyperactive PARP1. We characterized sublethal (1 μ mol/L, 2 h) and lethal (2 μ mol/L, 2 h) β -lap doses in 231-NQ+cells (Figure 2A), while 231-NQ-cells and normal primary human mammary epithelial cells remained non-responsive at either dose (Figures 2B, Supplemental Figure S3). ROS generation over time (% GSSG formation) in 231-NQ+cells exposed to lethal versus sublethal β -lap doses indicated no statistical differences (*p*>0.5) (Figure 2C) between treatments; use of %GSSG as an indicator of ROS was apparently not as sensitive an endpoint to discriminate sublethal versus lethal doses of β -lap (Figure 2C) compared to use of indicator dyes (Figures 1C, 1D). Interestingly, the chemical ROS scavenger, N-acetyl cysteine (NAC, given as pre-and co-treatments with β -lap), only partially protected cells against the lethal effects of 2, but not 3 μ mol/L, β -lap (Figure 2A). However, when NQO1 levels were partially inhibited by DIC, the efficacy of NAC was dramatically improved (Supplemental Figure S4), suggesting that NQO1-dependent redox cycling of β -lap produced ROS that could easily swamp the ROS scavenging effects of NAC. In contrast,

only minor levels of oxidative stress were noted in 231-NQ-cells at any β -lap dose tested (Figure 2D). These data suggested that although ROS scavengers were easily overwhelmed at low β -lap doses, factors such as NAC may play significant roles in protecting cells from sublethal or LD₅₀ doses that might be used in combination therapies (14).

Alkaline comet assays were then used to assess the extent of total DNA lesions (base damage, SSBs and double strand breaks) created by various β -lap doses in 231-NQ+ vs 231-NQ-cells (Figures 3A, B). Although a sublethal 1 μ mol/L β -lap dose produced significant GSSG formation (Figure 2C), this exposure caused significantly less DNA damage vs a lethal dose (2 μ mol/L an $\sim$ LD₇₀) (Figure 3A). All lethal β -lap doses (2–6 μ mol/L, Figure 3A) caused similar saturating levels of DNA lesions, consistent with elevated and saturated oxidized GSSG levels (Figure 2C). In contrast, β -lap treatment of 231-NQ-cells did not result in significant DNA lesions, consistent with the lack of OCR, ROS (H₂O₂) formation and lethality in NQO1-cells.

Exposure of 231-NQ+cells to a nonlethal β -lap (1 μ mol/L) dose did not result in measurable DNA lesions, loss of NAD⁺ or PAR-PARP1 formation (Figure 3A–3C). In contrast, treatment of NQO1+cells with cytotoxic β -lap doses (2 μ mol/L) resulted in significant NAD⁺ pool loss (Figure 3B) and PAR-PARP1 formation (Figure 3C), consistent with PARP1 hyperactivation (17), and steady state accumulation of post-translational PAR-modified and inactivated PARP1 (PAR, Figure 3C). Peak PAR-PARP1 formation was noted 30 min after 2 μ mol/L β -lap, whose time to peak levels decreased with increasing doses (Figure 3C, compare 2–6 μ mol/L β -lap exposures). Interestingly, loss of intracellular NAD⁺ levels were similar with all lethal doses of β -lap, strongly suggesting saturated PARP1 hyperactivation at all doses (Figure 3B).

Catalase detoxifies β -lap-induced H₂O₂ formation and is cytoprotective

Exogenous catalase (1000 U) significantly lowered H₂O₂ levels in β -lap-exposed 231-NQ+ cells (Figure 4A, left), while its addition had no effect on O₂^{•−} formation (not shown). Similarly, exogenous Mn²⁺-dependent superoxide dismutase (CuZnSOD, 3000 U) decreased O₂^{•−} formation (Figure 4A, right), while slightly increasing H₂O₂ levels (not shown). Forced over-expression of catalase in NQO1+MCF-7 cells (Figure 4B) using a CMV-driven expression vector (Open Biosystems) significantly spared NQO1+ MCF-7 cells from lethal β -lap doses (Figure 4C), ranging from 2–4 μ mol/L.

Similarly, exogenous catalase (500 U) significantly protected 231-NQ+cells from β -lap lethality (Figure 5A), while the survival of β -lap-treated 231-NQ-cells were not affected by the drug, with or without catalase co-addition (Figure 5B). Exogenous co-administration of catalase with CuZnSOD significantly decreased the effective catalase dose required to prevent β -lap-induced lethality (Figure 5C); for example, only 125 U of catalase was required with CuZnSOD to reach the same protection as 500 U catalase alone (Figures 5A, 5C, p<0.03, respectively). CuZnSOD enhanced the cytoprotective effects of all catalase doses used (Figures 5A, 5C (p 0.01), respectively)). Exogenous catalase did not influence the survival of β -lap-resistant 231-NQ-cells with or without CuZnSOD (Figure 5D), since OCR and ROS formation did not occur in the absence of NQO1 (Figure 1).

Catalase also significantly suppressed DNA damage in β -lap-exposed 231-NQ+ cells monitored by comet assays (Figure 6A), while β -lap-resistant 231-NQ-cells formed no DNA lesions after β -lap treatment, with or without catalase (Figure 6B). Consistently, catalase blocked β -lap-induced PARP1 hyperactivation (Figure 6C, upper panel), formation of H2AX (Figure 6C, lower panel), NAD⁺ loss (Figure 6D), downstream programmed necrosis-induced atypical PARP1 and p53 proteolytic cleavage (Figure 6E, Supplemental

Figure S5) and TUNEL+ responses (Figure 6F) that are uniquely associated with NQO1 bioactivatable drug lethality.

β-Lap-induced programmed necrosis is accompanied by nuclear AIF translocation

-Lap-treated MCF-7 cells (Supplemental Figure S6) undergo atypical PARP1 and p53 proteolysis (15) due to μ-calpain activation (16, 25), while treatment of the same cells with STS yielded classic apoptosis-related ~89 kDa PARP1 proteolysis (Supplemental Figure S6). BAPTA-AM, a calcium chelator, or DIC prevented -lap-induced programmed necrosis. In contrast, the pan-caspase inhibitor, Z-VAD (see supplemental Figure S1 for structure), had no effect on -lap-induced cell death or downstream PARP1/p53 proteolysis (Supplemental Figure S6), but blocked STS-related PARP1 cleavage (26).

Since μ-calpain activation can stimulate downstream AIF translocation from mitochondria (9, 27), inducing programmed cell death (9), we examined a role for AIF in -lap lethality. Indeed, activation and translocation of AIF from mitochondria (DMSO, Figure 7A) to nuclei was noted (4–24 h post-treatment, Figure 7A) in -lap-treated MCF-7 cells, consistent with μ-calpain activation kinetics (16, 25). AIF activation was blocked by BAPTA-AM (Figure 7B) or catalase (1000 U) co-treatments (Figure 7C). However, siRNA-mediated AIF knockdown only partially decreased the lethal effects of -lap in MCF-7 cells (Figure 7D), most likely due to simultaneous activation of other cell death mediators, including post-translational modification/activation of GAPDH (Figure 8) that mediates apoptotic-like cell death (28). Stable AIF knockdown in MDA-MB-231 cells, like those recently reported (29), resulted in dramatic morphology and growth alterations, with similar partial blockage of lethality noted in -lap-treated MCF-7 cells (Figure 7D). Thus, -lap stimulates multiple cell death factors, including μ-calpain (16, 25), AIF (Figure 7), and S-nitrosylated GAPDH (Figure 8).

Discussion

We used chemo-resistant MDA-MB-231 TNBC cells to link NQO1-dependent futile cycling of -lap to ROS-induced DNA damage and PARP1 hyperactivation. Threshold level responses in cells after -lap treatments were noted by sharp dose-dependent trigger events, mediated by robust H₂O₂ formation that, in turn, caused both DNA damage and Ca²⁺_{ER} release, ultimately leading to PARP1 hyperactivation (Supplemental Figure S7). H₂O₂ production was the obligate ROS inducing cell death after -lap, since catalase administration alone protected cells. PARP1 hyperactivation, both in dose-response and temporal kinetics of triggering cell death, resulted in catastrophic loss of essential nucleotides (NAD⁺ and ATP) that correlated well with '2 h minimum time to death' induced by -lap in NQO1+ expressing cells (17). Downstream, AIF activation and nuclear translocation (Figure 7) were consistent with our prior findings of μ-calpain activation (25), and previously described role(s) of μ-calpain in AIF activation by others (30). However, AIF activation is but one of a number of simultaneously activated cell death responses stimulated during -lap-induced programmed necrosis, and we were not able to completely protect cells by AIF knockdown alone, as others suggested (29). Differences in AIF knockdown could explain the conflicting results, however, our identification of various cell death factors (e.g., μ-calpain, AIF, GAPDH modification, as well as loss of essential nucleotides) simultaneously activated in -lap-exposed NQO1+ cells, make it unlikely that AIF abrogation alone would spare most -lap-exposed solid cancer cells. Although not explored in detail, the post-translational modification of GAPDH in -lap-treated NQO1+ cells has potentially important implications for understanding -lap-induced cell 'clean-up'. S-nitrosylation of GAPDH implies a potentially important role of nitric oxide species (NOS) (28) in -lap-induced lethality. GAPDH modification inhibits its functions in glycolysis (31, 32) and activates its DNA repair (33) and cell death (34) functions, suggesting dramatic

metabolic changes in exposed cancer cells due to this agent. Exposure to therapeutic -lap doses caused supra-lethal ROS levels and DNA damage that was not repaired, presumably due to loss of NAD⁺/ATP within ~60 min of exposure (Figure 3B). We are currently exploring the roles of NOS and posttranslational GAPDH in altered metabolism and repair in NQO1⁺ cells exposed to -lap.

We present the first evidence that H₂O₂ is the primary obligate ROS species necessary for -lap's lethal effects. A primary role for H₂O₂ is also consistent with the specific induction of SSBs caused by this promising tumor-selective antitumor agent. CuZnSOD specifically enhanced the efficacy of catalase to block -lap cytotoxicity in NQO1⁺ cancer cells. These data predict that normal tissue, which typically have higher catalase levels than cancer cells (35–37) could be selectively spared from toxicity caused by this agent. Alternatively, cancer cells over-expressing catalase and/or CuZnSOD would require higher doses of -lap to avoid “sublethal therapeutic treatments”. Accordingly, we propose that the ratio of NQO1 to catalase expression in tumor versus normal tissue is a major determinant of tumor-selectivity for -lap and future drugs that work by ‘NQO1 bioactivation’. On this point, it is interesting that an inverse correlation between NQO1 expression and catalase is noted across breast cancer cells (Supplemental Figure S8). However, we also noted that catalase expression in breast cancer cells was commonly low and did not dramatically affect the lethality of -lap-treated breast cancer cells that over-express NQO1. We predict that NQO1/Catalase ratio calculations are important when examining normal tissue *vs* tumor tissue, but that -lap-exposed NQO1 over-expressing cells will respond whether catalase is expressed or not, since ROS production can overwhelm catalase-mediated scavenging due to the futile cycle (Figure 1A).

Catalase protects cells from H₂O₂-induced lipid peroxidation that damages membranes and cellular organelles. Although exogenous catalase enhanced survival at low doses, excessive ROS and NOS formation by higher -lap doses (>6 μmol/L) were not inhibited by catalase alone. While CuZnSOD alone did not spare -lap-exposed NQO1⁺ cells, it enhanced the cytoprotective capacity of catalase. Combining CuZnSOD with catalase presumably converted superoxide to H₂O₂ that was easily detoxified by catalase to O₂ + 2H₂O.

-Lap-treated NQO1⁺ breast cancer cells, including TNBC cells, produce supra-lethal levels of ROS due to futile cycle metabolism of -lap specifically by NQO1. The mechanism of action of this agent involves PARP1 hyperactivation that triggers simultaneous redundant downstream lethal events, including essential nucleotide loss (NAD⁺ and ATP), AIF release, S-nitrosylation of GAPDH, and eventually programmed necrosis. Identification of ROS scavenging enzymes (i.e., SOD, catalase) that can partially suppress -lap-induced lethality is a crucial step in understanding resistance factors for this agent. Interrogation of expression of these factors may allow us to predict efficacious doses required for improved efficacy of NQO1 bioactivatable drugs, such as -lap, DNQ and their derivatives. Since NQO1 levels are over-expressed in breast cancer versus adjacent normal tissue (11), and particularly in ER⁺ breast cancer patients (38), these data strongly indicate use of this agent against breast, as well as many other solid tumors that specially over-expressed NQO1. Monitoring NQO1/catalase ratios in tumor *vs* normal tissue will be essential for ‘personalized therapies’ using -lap or other NQO1 bioactivatable drugs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We also acknowledge the imaging, mouse metabolism and flow cytometry cores, Simmons Comprehensive Cancer Center.

Grant Support

This work was supported by NIH/NCI grant CA102792 to D.A. Boothman and DoD Breast Cancer Pre-doctoral Fellowships to K.E. Reinicke (W81XWH-05-1-0248) and M.C. Srougi (W81XWH-04-1-0301).

Abbreviations list

-lap	-Lapachone
NQO1	NADPH quinone oxido reductase-1
PARP1	poly (ADP-ribose) polymerase-1
ROS	Reactive Oxygen Species
DIC	Dicoumarol

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin.* 2010; 60:277–300. [PubMed: 20610543]
2. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. *Clin Cancer Res.* 2009; 15:7479–7491. [PubMed: 20008848]
3. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. *Mayo Clin Proc.* 2009; 84:533–545. [PubMed: 19483170]
4. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. *Breast Cancer Res.* 2011; 13:202. [PubMed: 21392411]
5. O'Brien CS, Howell SJ, Farnie G, Clarke RB. Resistance to endocrine therapy: are breast cancer stem cells the culprits? *J Mammary Gland Biol Neoplasia.* 2009; 14:45–54. [PubMed: 19252972]
6. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. *Oncogene.* 2003; 22:7414–7430. [PubMed: 14576849]
7. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. *Cancer research.* 2012; 72:3038–3047. [PubMed: 22532167]
8. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev.* 2004; 18:1272–1282. [PubMed: 15145826]
9. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science.* 2002; 297:259–263. [PubMed: 12114629]
10. Zong WX, Thompson CB. Necrotic death as a cell fate. *Genes Dev.* 2006; 20:1–15. [PubMed: 16391229]
11. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. *Br J Cancer.* 1997; 76:923–929. [PubMed: 9328153]
12. Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. *Cancer Res.* 2010; 70:8088–8096. [PubMed: 20940411]
13. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, Cullen JJ. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. *Mol Carcinog.* 2005; 43:215–224. [PubMed: 16003741]

14. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. *Cancer Res.* 1989; 49:605–612. [PubMed: 2535961]
15. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. *J Biol Chem.* 2000; 275:5416–5424. [PubMed: 10681517]
16. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. *J Biol Chem.* 2001; 276:19150–19159. [PubMed: 11279125]
17. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. *J Biol Chem.* 2006; 281:33684–33696. [PubMed: 16920718]
18. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. *Proc Natl Acad Sci U S A.* 2007; 104:11832–11837. [PubMed: 17609380]
19. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. *Clin Cancer Res.* 2011; 17:275–285. [PubMed: 21224367]
20. Bentle MS, Bey EA, Dong Y, Reinicke KE, Boothman DA. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. *J Mol Histol.* 2006; 37:203–218. [PubMed: 16868862]
21. Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, et al. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. *Clin Cancer Res.* 2005; 11:3055–3064. [PubMed: 15837761]
22. Zhao W, Spitz DR, Oberley LW, Robbins ME. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. *Cancer Res.* 2001; 61:5537–5543. [PubMed: 11454704]
23. Goshe MB, Anderson VE. Hydroxyl radical-induced hydrogen/deuterium exchange in amino acid carbon-hydrogen bonds. *Radiat Res.* 1999; 151:50–58. [PubMed: 9973083]
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem.* 1951; 193:265–275. [PubMed: 14907713]
25. Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA. Mu-calpain activation in beta-lapachone-mediated apoptosis. *Cancer Biol Ther.* 2003; 2:141–152. [PubMed: 12750552]
26. Casiano CA, Ochs RL, Tan EM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. *Cell Death Differ.* 1998; 5:183–190. [PubMed: 10200463]
27. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. *Trends Pharmacol Sci.* 2004; 25:259–264. [PubMed: 15120492]
28. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. *Nat Cell Biol.* 2005; 7:665–674. [PubMed: 15951807]
29. Lee H, Park MT, Choi BH, Oh ET, Song MJ, Lee J, et al. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by beta-lapachone treatment. *PLoS One.* 2011; 6:e21533. [PubMed: 21738692]
30. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. *The Journal of biological chemistry.* 2005; 280:6447–6454. [PubMed: 15590628]
31. Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. *Cell Death Differ.* 2009; 16:1573–1581. [PubMed: 19779498]
32. Mohr S, Stamler JS, Brune B. Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. *The Journal of biological chemistry.* 1996; 271:4209–4214. [PubMed: 8626764]

33. Sirover MA. Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. *Life Sci.* 1996; 58:2271–2277. [PubMed: 8649216]
34. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. *J Cell Sci.* 2001; 114:1643–1653. [PubMed: 11309196]
35. Alexander NM. Catalase inhibition by normal and neoplastic tissue extracts. *The Journal of biological chemistry.* 1957; 227:975–985. [PubMed: 13463018]
36. Bannister WH, Bannister JV. Factor analysis of the activities of superoxide dismutase, catalase and glutathione peroxidase in normal tissues and neoplastic cell lines. *Free Radic Res Commun.* 1987; 4:1–13. [PubMed: 3506891]
37. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. *Breast cancer research : BCR.* 2011; 13:R87. [PubMed: 21914172]
38. Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, et al. NQO1 expression correlates inversely with NFκB activation in human breast cancer. *Breast Cancer Res Treat.* 2011
39. Chiu SM, Oleinick NL. Dissociation of mitochondrial depolarization from cytochrome c release during apoptosis induced by photodynamic therapy. *British journal of cancer.* 2001; 84:1099–1106. [PubMed: 11308261]
40. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, et al. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. *Cancer biology & therapy.* 2005; 4:95–102. [PubMed: 15662131]
41. Schonhoff CM, Matsuoka M, Tummala H, Johnson MA, Estevez AG, Wu R, et al. S-nitrosothiol depletion in amyotrophic lateral sclerosis. *Proceedings of the National Academy of Sciences of the United States of America.* 2006; 103:2404–2409. [PubMed: 16461917]

Figure 1. NQO1-dependent futile redox cycling of β -lap consumes O_2 and generates robust ROS

In A, Proposed futile redox cycle of β -Lap in the presence of NQO1, where the hydroquinone form of β -lap is unstable. Through two one-electron oxidations, that presumably use O_2 , the hydroquinone spontaneously reverts back to β -lap. This 'bioactivatable redox cycle' of β -lap, uses 60 moles NAD(P)H/mole β -lap in 5 min (15), consuming two moles O_2 per cycle, creating ~120 moles superoxide in 5 min. **In B**, left panel, cell extracts from NQO1-expressing (231-NQ+) or NQO1-deficient (231-NQ-) MDA-MB-231 TNBC cells were placed in a closed system with 1, 2 or 15 μ mol/L β -lap, $\pm$ dicoumarol (DIC), an NQO1 inhibitor, for 5 min. OCR was measured with an Ocean Optics O_2 sensor (left) as described in "Materials and Methods." Each bar represents X-fold OCR means, $\pm$ SE, of two independent experiments performed in triplicate. * p 0.05 (1 vs 2 μ mol/L β -lap); ** p 0.007 (15 μ mol/L β -lap $\pm$ 40 μ mol/L DIC). **In B**, right panel, O_2 consumption rates and proton production rates were measured in mock-treated (control) or

-Lap 4 $\mu\text{mol/L}$ exposed 231-NQ+ cells $\pm$ 40 $\mu\text{mol/L}$ DIC using the Seahorse XF24 Analyzer and Assay Wizard software. Data represent means, % treated/control (T/C,%) $\pm$ SE from quadruplicate samples. **In C–D**, -Lap-treated 231-NQ+ and 231-NQ– cells were analyzed for ROS formation at indicated times. Cells were stained with DHE (for O_2^-) in (C), or DCFDA (H_2O_2) in (D), and micrographs quantified as described (17) and in “Materials and Methods”. Doxorubicin (DOX, 5 $\mu\text{mol/L}$, 30 min), H_2O_2 (200 $\mu\text{mol/L}$, 30 min) were used as positive controls. Student’s *t*-tests were performed to determine significance between means of treatment conditions performed in triplicate, repeated three individual times.

Figure 2. NQO1-dependent, -lap-induced oxidative stress correlates with lethality

In A–B, 231-NQ⁺ and 231-NQ⁻ cells were exposed to -lap (μmol/L, 2 h) with or without 5mmol/L N-acetyl-L-cysteine (NAC) or 40 μmol/L dicoumarol and survival determined (17). **In C–D**, 231-NQ⁺ and 231-NQ⁻ cells were exposed to indicated -lap doses for varying times and reduced glutathione levels (%GSSG) assessed (17). Student's *t*-tests were performed and differences between means from three independent experiments were performed in sextuplet (A–B) or triplicate (C–D).

Figure 3. PARP1 hyperactivation is a determining factor in β -lap-induced programmed necrosis

In A, 231-NQ⁺ cells were treated with various β -lap doses as indicated and total DNA damage was measured by alkaline comet assays. Comet tails, a measure of DNA damage, were quantified using ImageJ software (17) and means $\pm$ SE from 50 individual cells per group from three independent experiments were measured. * $p < 0.01$ (to 6 μ mol/L, β -lap). **In B**, 231-NQ⁺ cells were treated with β -lap doses (1, 2, 4, or 6 μ mol/L) for the indicated times. Changes in NAD⁺ content were measured (18). **In C**, 231-NQ⁺ cells were treated with various β -lap doses for the indicated times and PARP1 hyperactivation monitored by PAR-PARP1 formation. PAR-modified PARP-1 appears as 116–118 kDa bands and

represents inactive PARP1. H₂O₂(200 μmol/L, 60 min) was used as a positive control for PAR-PARP1 formation. Shown are representative Western blots of experiments performed at least three times.

Figure 4. Catalase prevents β -lap-induced H_2O_2 formation and enhances clonogenic survival

In A, 231-NQ+ cells were treated with β -lap (4 $\mu\text{mol/L}$) in the presence or absence of 1000 U catalase or 3000 U CuZnSOD and stained with DHE or DCFDA for superoxide or H_2O_2 formation, respectively, as in Figure 1. H_2O_2 (200 $\mu\text{mol/L}$) or doxorubicin (5 $\mu\text{mol/L}$) exposures were for 30 min as positive controls. Shown are means, $\pm$ SE of integrated density values from representative digital images of at least 100 cells. Data are from experiments performed three independent times in triplicate. **In B** MCF-7 cells were transiently transfected with a CMV-driven catalase (CMV-CAT) expression vector or scrambled control vector (SCR), from Open Biosystems. Transfected MCF-7 cells were assayed for

catalase expression by western blot analysis. GAPDH levels were monitored as an internal loading control. ***In C***, MCF-7 cells were transiently transfected with CMV-CAT or SCR expression vectors. After 48 h, cells were trypsinized, counted and plated in 48-well dishes. After adhering for 24 h, cells were treated with -lap (closed circle or closed square = SCR or CMV-CAT transfected MCF-7 cells respectively) or -lap+ dicoumarol (open circle or square = SCR or CMV-CAT transfected MCF-7 cells respectively) at the indicated doses and survival assessed.

Figure 5. Exogenous catalase enhances clonogenic survival in MDA-MB 231-NQ⁺ cells
In A–B, 231-NQ⁺ (A) or 231-NQ⁻ (B) cells were treated with varying β -lap doses (μ mol/L) with or without various catalase doses (U, Units). Survival was assessed and results graphed as means $\pm$ SE of three experiments performed in sextuplicate. *In C–D*, 231-NQ⁺ or 231-NQ⁻ cells were treated with various β -lap doses for 2 h in the presence or absence of varying catalase doses, with or without 3000 U CuZnSOD. Following 2 h treatments, fresh media was added and survival assessed as in (A–B).

Figure 6. Exogenous catalase abrogates -lap-induced cytotoxicity

In A–B, 231-NQ+ or 231-NQ-cells were treated with -lap (4 μ mol/L, 2 h) with or without catalase (1000 U). Alkaline comet assays were then performed (17). Shown are comet tail means $\pm$ SE of at least 50 comet tails per condition. Student's *t* tests were performed to determine significance between groups. *In C* (upper panel), 231-NQ+ cells were treated with 4 μ mol/L -lap as indicated with (right) or without (left) catalase (1000 U). H₂O₂ (200 μ mol/L, 60 min) was used a positive control. Whole cell lysates were assessed for PARP1 hyperactivation (PAR-PARP1). -H2AX foci levels were assessed (lower panel) in 231-NQ+ cells exposed to 4 μ mol/L -lap (with or without 1000 U of Catalase) or 200 μ mol/L

H₂O₂. Foci formed in individual cells were assessed microscopically as described previously (17). **In D**, 231-NQ+ cells were treated with -lap (4 µmol/L, 2 h), with or without Catalase (1000 U), and with or without 40 µmol/L DIC. Cells were analyzed for NAD+ levels as in Figure 3 and data presented as means ±SE from three experiments performed in triplicate each. **In E**, 231-NQ+ cells were treated with varying doses of -lap for 2 h with (right) or without (left) catalase (1000 U). Whole cell lysates were analyzed for PARP1 and p53 proteolysis (15). **In F**, 231-NQ+ cells were treated with various -lap doses (1, 2, 4 or 6 µmol/L) with or without Catalase (1000 U) for 2 h and populations analyzed for TUNEL+ staining 48 h later (18). Data were graphed as X-fold TUNEL+ staining changes of -lap-exposed versus DMSO-treated cells ±SE from three independent experiments repeated in triplicate.

Figure 7. -Lap-induced cell death factor activation is abrogated by exogenous catalase
In A–C, MCF-7 cells were treated with -Lap (4 μ mol/L, 2h) (A), $\pm$ BAPTA-AM (5 μ mol/L) (B) or 1000 U catalase (C). Cells were then fixed and stained for AIF expression and Hoescht as described (39) and representative confocal micrographs taken at 100 $\times$ magnification. Both BAPTA-AM and catalase prevented AIF translocation from mitochondria to nuclei, and movement of mitochondria to perinuclear space. Mitochondria-specific staining confirmed AIF localization in organelles. **In D**, MCF-7 cells were transiently transfected with 20 μ mol/L siRNA specific for AIF or with scrambled nonsense siRNA as a control (40). Specific down-regulation of AIF expression was confirmed by Western blotting (see inset) using α -tubulin as a loading control. AIF relative levels (RL), were assessed by comparing densitometry scans (NIH imageJ software) of the loading control and AIF protein levels. Stable shRNA-AIF transfected MCF-7 or MDA-MB-231 cells had altered growth rates and morphology and were not used. After 48 h, cells were

treated with various -lap doses ($\mu\text{mol/L}$, 2 h), with or without 40 $\mu\text{mol/L}$ DIC and survival assessed as in Figure 2.

Figure 8. GAPDH proteolysis is induced during β -Lap-induced cell death

MCF-7 cells were treated with β -lap (4 μ mol/L, 2 h) and whole cell extracts monitored for PAR-PARP1, S-nitrosylated GAPDH (M-GAPDH) or total GAPDH (R-GAPDH) using antibodies that detect a specific site known to be S-nitrosylated (41) or a polyclonal antibody to GAPDH, respectively. MSH2 levels were monitored as an internal loading control.